Company: AEMD
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001683168-25-008271
Chunk: 57

Company: AETHLON MEDICAL INC
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 8
Chunk 57
---
-10 reverse stock split of its then outstanding shares of common stock, with trading of the post-split shares beginning October 20,
2025. Under the reverse stock split, every 10 shares of common stock held by stockholders were combined into one share, and any fractional
shares were rounded up to the next whole share. Following the split, the Company’s authorized common stock was adjusted accordingly
to 6,000,000 shares. The reverse stock split was effected proactively in anticipation of, and to address, Nasdaq’s minimum bid price
requirement for continued listing. The accompanying unaudited condensed consolidated financial statements and notes have been retroactively
revised to reflect the reverse stock split as if it had occurred on April 1, 2024, with all shares and per-share amounts revised accordingly.

On October 16, 2025, the Company received a notice
from Nasdaq stating that its common stock had been below $1.00 per share for 30 consecutive business days, resulting in noncompliance
with the minimum bid price requirement under Listing Rule 5550(a)(2) and pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company is not
eligible for any compliance period specified in Rule 5810(c)(3)(A) due to the fact that the Company has effected a reverse stock split
over the prior one-year period or has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio
of 250 shares or more to one. On October 31, 2025, the Company regained compliance with the minimum bid price requirement, and as such
on November 5, 2025, Nasdaq notified the Company that the matter is now closed. The Company remains in compliance with all other Nasdaq
continued listing requirements.

 17 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion of our financial condition
and results of operations should be read in conjunction with, and is qualified in its entirety by, the condensed consolidated financial
statements and notes thereto included in Item 1 in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion
and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business,
includes forward-looking statements that involve risks and uncertainties. For a complete discussion of forward-looking statements, see
the section above entitled